A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors
N. Sugamata et al., A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors, INT J ONCOL, 14(2), 1999, pp. 259-263
Effects of vorozole, a potent and specific nonsteroidal aromatase inhibitor
, were evaluated on female Sprague-Dawley (SD) rats with 7,12-dimethylbenz[
a] anthracene (DMBA)-induced mammary tumors. Vorozole at a dose of 0.25, 1.
0 and 4.0 mg/kg was orally administered once a day for 28 consecutive days.
A significant regression in tumor size was observed in each treated group
at 1, 2, 3 and 4 weeks after the start of treatment compared with control g
roup. Tissue insulin-like growth factor I (IGF-I) in the DMBA-induced tumor
s in each treated group significantly decreased in a dose-dependent fashion
compared with control group. These results show the mechanism of vorozole
in DMBA-induced rat mammary tumors.